Estimates Revisions Spero Therapeutics, Inc.
Stocks
SPRO
US84833T1034
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.230 USD | 0.00% |
|
0.00% | -47.21% |
| 07-27 | Spero Therapeutics, Inc. Announces Appointment of Debra Jeske Zack as Chief Medical Officer | CI |
| 07-15 | Innovent Biologics Shares Surge on Spero Deal That Could Be Worth $1.1 Billion | DJ |
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Earnings Per Share (EPS)
- Stock Market
- Stocks
- SPRO Stock
- Consensus Spero Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
